While the role of BDNF as a biomarker for depression and treatment outcome may be controversial (110), these results suggest the potential clinical importance of measuring peripheral BDNF concentrations and sleep quality in MDD patients to monitor changes over the course of treatment that may elucidate markers of clinical recovery. This evidence concerns the gene BDNF and depressive symptom measurement.